Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00605410

Enrollment

Registered

2008-01-31

Start date

2008-01-31

Completion date

2008-04-30

Last updated

2009-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Methacholine bronchoprovocation, Antimuscarinic

Brief summary

Certain lung disease medications can influence diagnostic tests and research investigations. This study will investigate how long ipratropium bromide must be withheld before a methacholine challenge test can be conducted. This information will be useful for validating current guidelines.

Interventions

DRUGipratropium bromide

2 puffs (40 micrograms) 2 puffs (0micrograms)

DRUGplacebo

Matched placebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

DIAGNOSTIC

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of asthma; stable and controlled * FEV1 greater than or equal to 65% predicted

Exclusion criteria

* Concomitant lung disease other than asthma

Design outcomes

Primary

Measure	Time frame
methacholine PC20	6hours and 12 hours post inhalation

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026